Clinical Trial Update: Endothelin Receptor Antagonism in Proteinuric Nephropathy [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial from the University of Edinburgh evaluating endothelin receptor antagonism for proteinuric nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Proteinuria

Snippet

Sponsor: University of Edinburgh | Conditions: Chronic Kidney Disease, Proteinuria | Phase 1 | Status: COMPLETED